



# **Cohere Medical Policy – Coronary Computed Tomography Angiography (CCTA), with or without Fractional Flow Reserve (FFR)**

*Clinical Guidelines for Medical Necessity Review*

**Version:** 3  
**Effective Date:** October 30, 2024

# Important Notices

## Notices & Disclaimers:

**GUIDELINES ARE SOLELY FOR COHERE'S USE IN PERFORMING MEDICAL NECESSITY REVIEWS AND ARE NOT INTENDED TO INFORM OR ALTER CLINICAL DECISION-MAKING OF END USERS.**

Cohere Health, Inc. ("**Cohere**") has published these clinical guidelines to determine the medical necessity of services (the "**Guidelines**") for informational purposes only, and solely for use by Cohere's authorized "**End Users**". These Guidelines (and any attachments or linked third-party content) are not intended to be a substitute for medical advice, diagnosis, or treatment directed by an appropriately licensed healthcare professional. These Guidelines are not in any way intended to support clinical decision-making of any kind; their sole purpose and intended use is to summarize certain criteria Cohere may use when reviewing the medical necessity of any service requests submitted to Cohere by End Users. Always seek the advice of a qualified healthcare professional regarding any medical questions, treatment decisions, or other clinical guidance. The Guidelines, including any attachments or linked content, are subject to change at any time without notice.

©2024 Cohere Health, Inc. All Rights Reserved.

## Other Notices:

HCPCS® and CPT® copyright 2024 American Medical Association. All rights reserved.

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

HCPCS and CPT are registered trademarks of the American Medical Association.

## Guideline Information:

**Specialty Area:** Diagnostic Imaging

**Guideline Name:** Cohere Medical Policy - Coronary Computed Tomography Angiography (CCTA), with or without Fractional Flow Reserve (FFR)

**Date of last literature review:** 7/25/2024

**Document last updated:** 10/30/2024

**Type:** ☒ Adult (18+ yo) | ☒ Pediatric (0-17 yo)

## **Table of Contents**

<b>Important Notices</b>	<b>2</b>
Table of Contents	3
<b>Medical Necessity Criteria</b>	<b>4</b>
<b>Service: Coronary Computed Tomography Angiogram (CCTA)</b>	
<b>with or without Fractional Flow Reserve (FFR)</b>	<b>4</b>
Recommended Clinical Approach	4
Medical Necessity Criteria	4
Indications	4
Non-Indications	6
Disclaimer on Radiation Exposure in Pediatric Population	7
Level of Care Criteria	8
Procedure Codes (CPT/HCPCS)	8
<b>Medical Evidence</b>	<b>9</b>
<b>References</b>	<b>10</b>
<b>Clinical Guideline Revision History/Information</b>	<b>13</b>

# Medical Necessity Criteria

**Service: Coronary Computed Tomography Angiogram (CCTA) with or without Fractional Flow Reserve (FFR)**

## Recommended Clinical Approach

Computed tomography coronary angiography (CCTA) is a non-invasive alternative to cardiac catheterization performed with iodinated contrast. The radiologist may consider additional phases, dynamic sequences, positioning of the patient, and the use of markers. The referring clinician is responsible for the appropriate clinical indication in consultation with a cardiac imaging expert. The patient's pertinent medical history should justify the exam. The physician laboratory director should choose the scanning protocol for the study before the patient's arrival. Following a positive CCTA, non-invasive fractional flow reserve (FFR) may be medically necessary to guide decisions about invasive coronary angiography in patients with intermediate or high-risk coronary anatomy on imaging.<sup>1-5</sup> CT-FFR is not recommended in patients with complex congenital heart disease.

## Medical Necessity Criteria

### Indications

→ **Computed tomography coronary angiography (CCTA) with or without FFR** is considered appropriate if **ANY** of the following is **TRUE**<sup>3,6-12</sup>:

- ◆ There is a suspicion of coronary artery anomalies<sup>12</sup>; **OR**
- ◆ Possible acute coronary syndrome which has stabilized without an acute MI (no evidence of myocardial injury such as a non-ST-Segment Elevation Myocardial Infarction [STEMI]); **OR**
- ◆ No known coronary artery disease (CAD) with an intermediate-high pre-test probability of obstructive CAD (based on symptoms and objective cardiovascular data) and **ANY** of the following<sup>3,12,13-21</sup>:
  - Stable chest pain (or ischemic equivalent) after an inconclusive or abnormal exercise ECG or stress imaging study; **OR**
  - Stable chest pain (or ischemic equivalent) after a negative stress test but with high clinical suspicion of CAD; **OR**
  - Stable chest pain (or ischemic equivalent); **OR**

- ◆ CAD is known and previously determined to be non-obstructive (less than 50%), but there has been a clinical change that suggests CAD in the native coronary arteries has progressed<sup>13</sup>; **OR**
- ◆ Previous coronary revascularization was performed and there is a clinical change suggesting CAD progression in bypass grafts, in stented vessels with a diameter greater than 3mm, or in ungrafted coronary arteries; **OR**
- ◆ Acute chest pain with suspected aortic dissection<sup>12</sup>; **OR**
- ◆ Dyspnea with suspected cardiac origin<sup>15-16</sup>; **OR**
- ◆ Unexplained congestive heart failure<sup>16</sup>; **OR**
- ◆ Presyncope or syncope (if clinical symptoms or signs are consistent with a cardiac diagnosis known to cause presyncope/syncope, including but not limited to hypertrophic cardiomyopathy and heart failure)<sup>17-18</sup>; **OR**
- ◆ Nontraumatic aortic disease<sup>19</sup>; **OR**
- ◆ FFR is for **ANY** of the following<sup>20,21</sup>:
  - For functional evaluation of coronary CTA lesions, which are 40–90% stenosed in a proximal to a middle coronary segment on CCTA<sup>3,20</sup>; **OR**
  - For evaluating multivessel disease and identifying culprit lesions seen on CCTA that may be causing symptoms; **OR**
  - For evaluating the physiologic severity of multiple lesions in a single vessel<sup>3</sup>; **OR**
- ◆ FFR may be repeated if a CCTA has been performed within the preceding month and **ALL** of the following are **TRUE**:
  - There is documented clinical necessity; **AND**
  - No existing follow-up guideline for that indication; **AND**
  - Prior imaging results of the specific area or structure, obtained using the same imaging modality, must be documented and available for comparison; **AND**
  - **ANY** of the following is **TRUE**:
    - A change in clinical status has occurred (e.g., worsening or new symptoms) that may influence the treatment approach; **OR**
    - The requirement for interval reassessment, which may alter the treatment plan; **OR**
    - One-time follow-up of a prior indeterminate finding to assess for interval change; **OR**
    - Reimaging is needed either before or after

performing an invasive procedure; **OR**

- ◆ Repeat imaging (defined as repeat request following recent imaging of the same anatomic region with the same modality), in the absence of established guidelines, will be considered reasonable and necessary if **ANY** of the following is **TRUE**:
  - New or worsening symptoms, such that repeat imaging would influence treatment; **OR**
  - One-time clarifying follow-up of a prior indeterminate finding; **OR**
  - In the absence of change in symptoms, there is an established need for monitoring which would influence management.

## Non-Indications

→ **Computed tomography coronary angiography (CCTA)** is not considered appropriate if **ANY** of the following is **TRUE**<sup>5,11</sup>:

- ◆ The patient has undergone advanced imaging of the same body part within 3 months without undergoing treatment or developing new or worsening symptoms<sup>22</sup>; **OR**
- ◆ If **ANY** of the following is **TRUE** if contrast is used:
  - History of anaphylactic allergic reaction to iodinated contrast media; **OR**
  - Renal insufficiency with no provided detailed guidelines; **OR**
- ◆ The patient uses metformin (if not held); **OR**
- ◆ The patient has uncontrolled rapid atrial fibrillation; **OR**
- ◆ Normal coronary angiogram or CCTA with no stenosis or plaque within the last two years and stable symptoms; **OR**
- ◆ Normal stress test within the previous year (given adequate stress) with stable symptoms; **OR**
- ◆ If FFR is performed, it is not considered appropriate if **ANY** of the following conditions is **TRUE**<sup>3,21,23</sup>:
  - The original CCTA was of suboptimal quality; **OR**
  - The patient is not a candidate for revascularization; **OR**
  - The patient has a metal intracoronary stent in the vessel to be studied; **OR**
  - Coronary anatomy seen on CCTA is non-obstructive<sup>20</sup>; **OR**
  - The patient has complex congenital heart disease; **OR**
  - There is a contraindication to the use of adenosine.

\*NOTE: CT in patients with claustrophobia should be requested at the discretion of the ordering provider.

\*\*NOTE: CT in pregnant patients should be requested at the discretion of the ordering provider and obstetric care provider.

### **Disclaimer on Radiation Exposure in Pediatric Population**

Due to the heightened sensitivity of pediatric patients to ionizing radiation, minimizing exposure is paramount. At Cohere, we are dedicated to ensuring that every patient, including the pediatric population, has access to appropriate imaging following accepted guidelines. Radiation risk is dependent mainly on the patient's age at exposure, the organs exposed, and the patient's sex, though there are other variables. The following technical guidelines are provided to ensure safe and effective imaging practices:

**Radiation Dose Optimization:** Adhere to the lowest effective dose principle for pediatric imaging. Ensure that imaging protocols are specifically tailored for pediatric patients to limit radiation exposure.<sup>[24,25](#)</sup>

**Alternative Modalities:** Prioritize non-ionizing imaging options such as ultrasound or MRI when clinically feasible, as they are less likely to expose the patient to ionizing radiation. For instance, MRI or ultrasound should be considered if they are more likely to provide an accurate diagnosis than CT, fluoroscopy, or radiography.<sup>[24,25](#)</sup>

**Cumulative Dose Monitoring:** Implement systems to track cumulative radiation exposure in pediatric patients, particularly for those requiring multiple imaging studies. Regularly reassess the necessity of repeat imaging based on clinical evaluation.<sup>[24,25](#)</sup>

**CT Imaging Considerations:** When CT is deemed the best method for achieving a correct diagnosis, use the lowest possible radiation dose that still yields reliable diagnostic images.<sup>[24,25](#)</sup>

### **Cohere Imaging Gently Guideline**

The purpose of this guideline is to act as a potential override when clinically indicated to adhere to Imaging Gently and Imaging Wisely guidelines and As Low As Reasonably Possible (ALARA) principles.

## **Level of Care Criteria**

Outpatient

### **Procedure Codes (CPT/HCPCS)**

<b>CPT/HCPCS Code</b>	<b>Code Description</b>
75574	Computed tomographic angiography (CTA), heart, coronary arteries and bypass grafts (when present); with contrast material, including 3D image postprocessing (including evaluation of cardiac structure and morphology, assessment of cardiac function, and evaluation)
75580	Noninvasive estimate of coronary fractional flow reserve (FFR) derived from augmentative software analysis of the data set from a coronary computed tomography angiography, with interpretation and report by a physician or other qualified healthcare professional



## Medical Evidence

In the 2021 chest pain guideline for the American College of Cardiology, Gulati et al. give several recommendations for the use of coronary computed tomography angiography (CCTA), including for intermediate-risk patients with acute chest pain and no known coronary artery disease (CAD) who require diagnostic testing following a negative evaluation for acute coronary syndrome. Additionally, CCTA is a proven approach for evaluating patients with stable chest pain with a strong (Class 1) strength of recommendation<sup>3</sup>. The writers state that CCTA helps exclude atherosclerotic plaque and obstructive CAD. A recommendation was given for CCTA to diagnose obstructive CAD in patients at intermediate risk with acute pain and mildly abnormal previous stress testing. When evaluating patients in the emergency department with acute chest pain, CCTA may reduce the time to diagnosis and possible earlier safe discharge.<sup>3</sup>

Taylor et al. (2010) developed appropriate use criteria for cardiac computed tomography. The use of CCTA in low or intermediate-risk patients with pretest probability for CAD may be considered. Testing in high-risk patients, routinely repeating testing, and use for general cardiac screening were not viewed favorably. Lowest appropriateness ratings were assigned in urgent presentations with acute symptoms with suspicion of acute coronary syndrome, such as in definite myocardial infarction (MI), persistent ST-segment elevation on ECG (when MI excluded), and acute chest pain of uncertain cause prompting rule out of pulmonary embolism, aortic dissection and acute coronary syndrome.<sup>6</sup>

Driessen and colleagues (2019) published post hoc single-center study results comparing CCTA, FFR, and perfusion imaging for ischemia diagnosis for the American College of Cardiology. The 208 patients were enrolled with suspicion of CAD and underwent CCTA, SPECT, and PET scans with routine FFR study of all major coronary arteries. All patients were prospectively tested noninvasively and invasively with FFR within 2 weeks, regardless of their results. Of the 208 patients, the CCTA images of 75% of patients were entirely sufficient for evaluation by FFR<sub>CT</sub>. The group concluded that FFR<sub>CT</sub> showed high diagnostic performance for vessel-specific ischemia, provided that the CCTA images were adequate for FFR evaluation. PET scanning yielded the highest diagnostic performance due to the often high rejection rate of the FFR<sub>CT</sub>.<sup>9</sup>

## References

1. Villines TC, American College of Cardiology. Coronary CTA should be the initial test in most patients with stable chest pain: PRO. American College of Cardiology. <https://www.acc.org/latest-in-cardiology/articles/2018/05/21/06/37/coronary-cta-pro>. Published May 21, 2018. Accessed July 1, 2024.
2. Poon M, Lesser JR, Biga C, et al. Current evidence and recommendations for coronary cta first in evaluation of stable coronary artery disease. *J Am Coll Cardiol*. 2020;76(11):1358–1362. doi: 10.1016/j.jacc.2020.06.078.
3. Gulati M, Levy PD, Mukherjee D, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR guideline for the evaluation and diagnosis of chest pain. *J Am Coll Cardiol*. 2021 Nov 30;78(22):e187–e285. doi: 10.1016/j.jacc.2021.07.053. PMID: 34756653.
4. American College of Radiology (ACR), North American Society of Cardiovascular Imaging (NASCI), Society for Pediatric Radiology (SPR). ACR–NASCI–SPR practice parameter for the performance and interpretation of cardiac computed tomography (CT) – resolution 45. Updated 2021. Accessed July 1, 2024. <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/CardiacCT.pdf>.
5. Abbata S, Blanke P, Maroules CD, et al. SCCT guidelines for the performance and acquisition of coronary computed tomographic angiography: A report of the Society of Cardiovascular Computed Tomography Guidelines Committee: Endorsed by the North American Society for Cardiovascular Imaging (NASCI). *J Cardiovasc Comput Tomogr*. 2016 Nov–Dec;10(6):435–449. doi: 10.1016/j.jcct.2016.10.002. PMID: 27780758.
6. Taylor AJ, Cerqueira M, et al. ACCF/SCCT/ACR/AHA/ASE/ASNC/NASCI/SCAI/SCMR 2010 Appropriate Use Criteria for Cardiac Computed Tomography. *Circulation*. 2010 Nov 23;122(21):e525–55. doi: 10.1161/CIR.0b013e3181fcae66. PMID: 20975004.
7. Bellinge JW, Majeed K, Carr SS, et al. Coronary artery 18F–NaF PET analysis with the use of an elastic motion correction software. *J Nucl Cardiol*. 2020 Jun;27(3):952–961. doi: 10.1007/s12350-018-01587-7. PMID: 30684262.
8. Sanz J. Imaging of Coronary Disease Hemodynamic Significance: And the Winner Is... *J Am Coll Cardiol*. 2019 Jan 22;73(2):174–176. doi: 10.1016/j.jacc.2018.10.055. PMID: 30654889.
9. Driessen RS, Danad I, Stuijzand WJ, et al. Comparison of coronary computed tomography angiography, fractional flow reserve, and

- perfusion imaging for ischemia diagnosis. *J Am Coll Cardiol*. 2019 Jan 22;73(2):161-173. doi: 10.1016/j.jacc.2018.10.056. PMID: 30654888.
10. Cheung BMY. Coronary CT angiography and subsequent risk of myocardial infarction. *N Engl J Med*. 2019 Jan 17;380(3):299-300. doi: 10.1056/NEJMc1816189. PMID: 30653282 .
  11. Wolk MJ, Bailey SR, Doherty JU, et al. ACCF/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2013 multimodality appropriate use criteria for the detection and risk assessment of stable ischemic heart disease: A report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons. *J Am Coll Cardiol*. 2014 Feb 4;63(4):380-406. doi: 10.1016/j.jacc.2013.11.009. PMID: 24355759.
  12. Narula J, Chandrashekar Y, Ahmadi A, et al. SCCT 2021 expert consensus document on coronary computed tomographic angiography: A report of the society of cardiovascular computed tomography. *J Cardiovasc Comput Tomogr*. 2021 May-Jun;15(3):192-217. doi: 10.1016/j.jcct.2020.11.001. PMID: 33303384; PMCID: PMC8713482.
  13. Newby DE, Adamson PD, Berry C, et al. Coronary CT angiography and 5-year risk of myocardial infarction. *N Eng J Med*. 2018 Sep 6;379(10):924-933. doi: 10.1056/NEJMoal805971. PMID: 30145934.
  14. Expert Panel on Cardiac Imaging, Batlle JC, Kirsch J, et al. ACR appropriateness criteria – chest pain, possible acute coronary syndrome. *J Am Coll Radiol*. 2020 May;17(5S):S55-S69. doi: 10.1016/j.jacr.2020.01.027. PMID: 32370978.
  15. Expert Panel on Cardiac Imaging, Bolen MA, Saeedan MNB, et al. ACR appropriateness criteria – dyspnea-suspected cardiac origin (ischemia already excluded): 2021 update. *J Am Coll Radiol*. 2022 May;19(5S):S37-S52. doi: 10.1016/j.jacr.2022.02.014. PMID: 35550804.
  16. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. 2022;145(18):e895-e1032. doi: 10.1161/CIR.0000000000001063. PMID: 35363499. Erratum in: *Circulation*. 2022 May 3;145(18):e1033.
  17. Expert Panels on Cardiac Imaging and Neurological Imaging, Kligerman SJ, Bykowski J, et al. ACR appropriateness criteria – syncope. *J Am Coll Radiol*. 2021 May;18(5S):S229-S238. doi: 10.1016/j.jacr.2021.02.021. PMID: 33958116.

18. Devitt M. Diagnosis of stable ischemic heart disease: Recommendations from the ACP. *Am Fam Phys*. 2013;88(7):469–470.  
<https://www.aafp.org/pubs/afp/issues/2013/1001/p469.html>.
19. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. 2021;143(5):e72–e227. doi: 10.1161/CIR.0000000000000923. PMID: 33332150. Erratum in: *Circulation*. 2021 Feb 2;143(5):e229].
20. Norgaard BL, Fairbairn TA, Safian RD, et al. Coronary CT angiography-derived fractional flow reserve testing in patients with stable coronary artery disease: Recommendations on interpretation and reporting. *Radiol Cardiothorac Imaging*. 2019 Nov 21;1(5):e190050. doi: 10.1148/ryct.2019190050. PMID: 33778528; PMCID: PMC7977999.
21. Xaplanteris P, Fournier S, Pijls NHJ, et al. Five-year outcomes with PCI guided by fractional flow reserve. *N Engl J Med*. 2018 Jul 19;379(3):250–259. doi: 10.1056/NEJMoal803538. PMID: 29785878.
22. Wasser EJ, Prevedello LM, Sodickson A, Mar W, Khorasani R. Impact of a real-time computerized duplicate alert system on the utilization of computed tomography. *JAMA Intern Med*. 2013;173(11):1024–1026. doi: 10.1001/jamainternmed.2013.543. PMID: 23609029.
23. Edvardsen T, Asch FM, Davidson B, et al. Non-invasive imaging in coronary syndromes: Recommendations of the European Association of Cardiovascular Imaging and the American Society of Echocardiography, in collaboration with the American Society of Nuclear Cardiology, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. *Eur Heart J Cardiovasc Imaging*. 2022 Jan 24;23(2):e6–e33. doi: 10.1093/ehjci/jeab244. PMID: 34751391.
24. United States Food and Drug Administration (FDA). De novo classification request for FFR<sub>CT</sub> V. 1.4. (submission number DEN130045). Published November 6, 2013. Accessed July 1, 2024.  
[https://www.accessdata.fda.gov/cdrh\\_docs/reviews/DEN130045.pdf](https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN130045.pdf).
25. The Image Gently Alliance. Procedures - cardiac imaging. Updated 2014. Accessed June 26, 2024.  
<https://www.imagegently.org/Procedures/Cardiac-Imaging>.
26. National Cancer Institute. Radiation risks and pediatric computed tomography (CT): A guide for health care. Updated September 4, 2018. Accessed June 26, 2024.  
<https://www.cancer.gov/about-cancer/causes-prevention/risk/radiation/pediatric-ct-scans>.

# Clinical Guideline Revision History/Information

Original Date: April 15, 2022		
Review History		
Version 2	8/2/2024	Annual review and policy restructure.
Version 3	10/30/2024	Edited repeat imaging criteria language.